UK govt offers "step change" in support of regenerative medicine
This article was originally published in Clinica
The UK is at the forefront of regenerative medicine (RM) and has "huge potential" to produce commercially viable therapies and other technologies for a range of diseases. However, for this to happen, the right kind of regulatory and financial support must be provided, a range of scientific and other issues must be overcome, and companies must choose carefully what kind of products or technologies they are prepared to invest in.
You may also be interested in...
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.